Influence of Bacterial Culture Medium on Peptidoglycan Binding of Cell Wall Lytic Enzymes.

[1]  Yftah Tal‐Gan,et al.  Attenuating the Selection of Vancomycin Resistance Among Enterococci Through the Development of Peptide-Based Vancomycin Antagonists. , 2020, ACS infectious diseases.

[2]  D. Burgess,et al.  Focusing the Lens on the CAMERA Concepts: Early Combination β-Lactam and Vancomycin Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia , 2020, Antimicrobial Agents and Chemotherapy.

[3]  P. García,et al.  Encapsulation of the Antistaphylococcal Endolysin LysRODI in pH-Sensitive Liposomes , 2020, Antibiotics.

[4]  Nadja Leimer,et al.  Targeting Hidden Pathogens: Cell-Penetrating Enzybiotics Eradicate Intracellular Drug-Resistant Staphylococcus aureus , 2020, mBio.

[5]  J. Dordick,et al.  Reducing Staphylococcus aureus resistance to lysostaphin using CRISPR‐dCas9 , 2019, Biotechnology and bioengineering.

[6]  Jungbae Kim,et al.  Modular Assembly of Unique Chimeric Lytic Enzymes on a Protein Scaffold Possessing Anti-Staphylococcal Activity. , 2019, Biomacromolecules.

[7]  C. Collins,et al.  Selective antimicrobial activity of cell lytic enzymes in a bacterial consortium , 2019, Applied Microbiology and Biotechnology.

[8]  J. Bujnicki,et al.  Structural bases of peptidoglycan recognition by lysostaphin SH3b domain , 2019, Scientific Reports.

[9]  M. Tyers,et al.  Drug combinations: a strategy to extend the life of antibiotics in the 21st century , 2019, Nature Reviews Microbiology.

[10]  Aastha Chokshi,et al.  Global Contributors to Antibiotic Resistance , 2019, Journal of global infectious diseases.

[11]  A. Buckle,et al.  Catalytic diversity and cell wall binding repeats in the phage‐encoded endolysins , 2018, Molecular microbiology.

[12]  J. Azeredo,et al.  Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy , 2018, Viruses.

[13]  J. Dordick,et al.  Unprotonated Short-Chain Alkylamines Inhibit Staphylolytic Activity of Lysostaphin in a Wall Teichoic Acid-Dependent Manner , 2018, Applied and Environmental Microbiology.

[14]  C. São-José.  Engineering of Phage-Derived Lytic Enzymes: Improving Their Potential as Antimicrobials , 2018, Antibiotics.

[15]  R. Dobson,et al.  Potential for Bacteriophage Endolysins to Supplement or Replace Antibiotics in Food Production and Clinical Care , 2018, Antibiotics.

[16]  Y. Briers,et al.  Synthetic biology of modular endolysins. , 2017, Biotechnology advances.

[17]  M. Schmelcher,et al.  Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies , 2017, Clinical Microbiology Reviews.

[18]  R. Buey,et al.  Deciphering how Cpl-7 cell wall-binding repeats recognize the bacterial peptidoglycan , 2017, Scientific Reports.

[19]  Jungbae Kim,et al.  Biocatalytic Nanocomposites for Combating Bacterial Pathogens. , 2017, Annual review of chemical and biomolecular engineering.

[20]  C. Brun-Buisson,et al.  Estimating the morbidity and mortality associated with infections due to multidrug-resistant bacteria (MDRB), France, 2012 , 2016, Antimicrobial Resistance and Infection Control.

[21]  Krunal K. Mehta,et al.  Wall Teichoic Acids Are Involved in the Medium-Induced Loss of Function of the Autolysin CD11 against Clostridium difficile , 2016, Scientific Reports.

[22]  Ruopeng Cai,et al.  LysGH15 kills Staphylococcus aureus without being affected by the humoral immune response or inducing inflammation , 2016, Scientific Reports.

[23]  C. São-José,et al.  More than a hole: the holin lethal function may be required to fully sensitize bacteria to the lytic action of canonical endolysins , 2016, Molecular microbiology.

[24]  Krunal K. Mehta,et al.  Binding domains of Bacillus anthracis phage endolysins recognize cell culture age‐related features on the bacterial surface , 2015, Biotechnology progress.

[25]  P. M. Pereira,et al.  Cell shape dynamics during the staphylococcal cell cycle , 2015, Nature Communications.

[26]  D. Donovan,et al.  Antimicrobial bacteriophage-derived proteins and therapeutic applications , 2015, Bacteriophage.

[27]  C. São-José,et al.  EC300: a phage-based, bacteriolysin-like protein with enhanced antibacterial activity against Enterococcus faecalis , 2015, Applied Microbiology and Biotechnology.

[28]  K. Griswold,et al.  Discovery of novel S. aureus autolysins and molecular engineering to enhance bacteriolytic activity , 2015, Applied Microbiology and Biotechnology.

[29]  T. Bernhardt,et al.  Beta-Lactam Antibiotics Induce a Lethal Malfunctioning of the Bacterial Cell Wall Synthesis Machinery , 2014, Cell.

[30]  P. François,et al.  Generation of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS. , 2014, The Journal of antimicrobial chemotherapy.

[31]  Y. Tor,et al.  Antibiotics and Bacterial Resistance in the 21st Century , 2014, Perspectives in medicinal chemistry.

[32]  M. Loessner,et al.  Bacteriophage endolysins as novel antimicrobials. , 2012, Future microbiology.

[33]  K. Bush.  Antimicrobial agents targeting bacterial cell walls and cell membranes. , 2012, Revue scientifique et technique.

[34]  V. Fischetti.  Exploiting what phage have evolved to control gram-positive pathogens , 2011, Bacteriophage.

[35]  Troy Day,et al.  The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy , 2011, Proceedings of the National Academy of Sciences.

[36]  T. Bugg,et al.  Bacterial cell wall assembly: still an attractive antibacterial target. , 2011, Trends in biotechnology.

[37]  W. Xu,et al.  LysGH15, a Novel Bacteriophage Lysin, Protects a Murine Bacteremia Model Efficiently against Lethal Methicillin-Resistant Staphylococcus aureus Infection , 2010, Journal of Clinical Microbiology.

[38]  D. Aksoy,et al.  New antimicrobial agents for the treatment of Gram-positive bacterial infections. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[39]  J. Whisstock,et al.  The 1.6 A crystal structure of the catalytic domain of PlyB, a bacteriophage lysin active against Bacillus anthracis. , 2007, Journal of molecular biology.

[40]  T. Nakae,et al.  Trends of β-lactam antibiotic susceptibility in blood-borne methicillin-resistant Staphylococcus aureus (MRSA) and their linkage to the staphylococcal cassette chromosome mec (SCCmec) type , 2007, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[41]  I. Korndörfer,et al.  The crystal structure of the bacteriophage PSA endolysin reveals a unique fold responsible for specific recognition of Listeria cell walls. , 2006, Journal of molecular biology.

[42]  V. Fischetti,et al.  PlyPH, a Bacteriolytic Enzyme with a Broad pH Range of Activity and Lytic Action against Bacillus anthracis , 2006, Journal of bacteriology.

[43]  Vincent A. Fischetti,et al.  Phage Lytic Enzyme Cpl-1 as a Novel Antimicrobial for Pneumococcal Bacteremia , 2003, Infection and Immunity.

[44]  Julie A. Wu,et al.  Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces , 2003, Antimicrobial Agents and Chemotherapy.

[45]  Karl Kramer,et al.  C‐terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high‐affinity binding to bacterial cell wall carbohydrates , 2002, Molecular microbiology.

[46]  E. Díaz,et al.  Studies on the structure and function of the N‐terminal domain of the pneumococcal murein hydrolases , 1992, Molecular microbiology.

[47]  L. Philipson,et al.  Factors Affecting Competence for Transformation in Staphylococcus aureus , 1974, Journal of bacteriology.